ArticleBMC infectious diseases2026
Epidemiological characteristics of people living with HIV on antiretroviral therapy (ART) in Pointe-Noire, Republic of congo.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
introductionHIV infection continues to be a major contributor to morbidity and mortality in developing countries, including the Republic of the Congo. The progression of the infection to advanced stages is influenced by various factors such as viral genetics, host immune responses variation, body mass index (BMI), treatment interruption or lack of treatment access. This study describes the characteristics of HIV patients on ART and identifies factors associated with viral load suppression in a Congolese urban population.
methodsThis cross-sectional study was conducted from June to July 2021 in Pointe Noire. Patients were recruited at the ‘Centre Association Avenir Positif’. Following a clinical evaluation by a healthcare provider, socio-behavioral, sociodemographic, and clinical data were extracted from patients updated medical records, in addition 5 mL of individual blood was sampled for viral load measurement, using Xpert®-HIV-1 Viral Load assay.
resultsA total of 510 known HIV positive patients were included in this study. Most of them were women 311 (61%). The analysis revealed a positive association (p = 0.022) between age groups and HIV disease stage, with stage II more prevalent in younger patients (1–17 years) and stage III more common in adults (18–50 years). Tuberculosis (15.6% at Stage I, 36.44% at Stage II, and 51.7% at Stage III) (p < 0.001) and candidiasis (p = 0.023) were two opportunistic infections significantly associated with the advanced stages of the disease. In addition, a significant association was found between treatment interruption (11.6%) and the advanced phase of the disease (Stage III, p < 0.01). Body mass index was significantly associated with advanced stage of the disease: the proportion of cases with elevated BMI was high in Stage III (58.6%; p = 0.041). Finally, patients who delayed initiating antiretroviral treatment more than five years after being tested HIV positive were 2.33 times more likely to have an unsuppressed viral load (p = 0.073).
conclusionFactors such as tuberculosis, candidiasis, treatment interruption, underweight and delaying antiretroviral treatment initiation were significantly associated with the disease severity. Regular monitoring of these factors is essential for tracking HIV/AIDS status and improving patient management and clinical counseling. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.